The capital raise provides cash runway into 2029, removing near-term financing risk, but the 14.92% discount and dilution are negative for existing holders. The actual offering size (2.2M shares + 345K warrants) is far smaller than the 75M shares initially registered, which may relieve some overhang fears. Monitor for any further secondary offerings and clinical data readouts for JNJ-1900 (NBTXR3) and Nanoprimer platforms.
Price Chart
Executive Summary
Nanobiotix announced the full exercise of the underwriters' over-allotment option in its global offering, increasing total gross proceeds to approximately $100 million. The offering includes 2,218,467 ordinary shares and 345,099 pre-funded warrants, with proceeds expected to fund operations into 2029. This follows a preliminary prospectus supplement filed two days ago that signaled massive potential dilution, though the actual offering size is far smaller than the 75 million shares initially registered.
Key Facts
- Underwriters fully exercised over-allotment option for 33,805 additional ADSs at $38.98/ADS
- Total gross proceeds from global offering now approximately $100 million
- Total securities issued: 2,218,467 ordinary shares and 345,099 pre-funded warrants
- Offering priced at €33.60 per ordinary share, a 14.92% discount to VWAP over prior three trading sessions
- Net proceeds expected to fund operations into 2029
- Proceeds allocation: <10% to JNJ-1900 (NBTXR3), 50-60% to Nanoprimer and other platforms, 30-40% for general corporate purposes
- This follows a preliminary prospectus supplement on May 20 for up to 75 million shares (~155% dilution), though actual offering is much smaller
Financial Impact
Approximately $100 million gross proceeds raised, with ~4.5% dilution from the base offering plus additional 33,805 ADSs from over-allotment. The 14.92% discount to recent VWAP represents a material cost to existing shareholders.
Risk Factors
- Dilution from the offering and pre-funded warrants reduces EPS and ownership percentage for existing shareholders
- 14.92% discount to VWAP signals weak demand at market price
- Proceeds heavily weighted toward early-stage Nanoprimer platform (50-60%), which carries higher clinical risk
- Potential for additional offerings if cash burn accelerates or clinical milestones are delayed
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003653 |
| Document: f6k_052226.htm | 0001171843-26-003653 |
| Document: 0001171843-26-003653-index-headers.html | 0001171843-26-003653 |
| Document: 0001171843-26-003653-index.html | 0001171843-26-003653 |
| Document: 0001171843-26-003653.txt | 0001171843-26-003653 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 5, 2026 20w ago | 6-K | — | awaiting T+20 | — | — |
Jun 2, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 26, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 26, 2026 21w ago | 6-K | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | 424B5 | — | awaiting T+20 | — | — |
May 21, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 21, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 20, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 20, 2026 22w ago | 424B5 | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers